Response of retinal sensitivity to ranibizumab treatment of macular edema after acute branch retinal vein occlusion

Retina

Volumn 33, Issue 6, 2013, Pages 1220-1226

  Mylonas, Georgios ^a   Sacu, Stefan ^a   Dunavoelgyi, Roman ^a   Matt, Gerlinde ^a   Blum, Robert ^a   Buehl, Wolf ^a   Pruente, Christan ^a   Schmidt Erfurth, Ursula ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

branch retinal vein occlusion; central retinal thickness; macular edema; ranibizumab; retinal sensitivity

Indexed keywords

RANIBIZUMAB;

ACUTE DISEASE; ADULT; AGED; ARTICLE; BRANCH RETINAL VEIN OCCLUSION; CENTRAL MACULAR THICKNESS; CENTRAL RETINAL THICKNESS; CLINICAL ARTICLE; CORRELATION ANALYSIS; DIFFERENTIAL THRESHOLD; EYE PHOTOGRAPHY; FEMALE; FOLLOW UP; FUNCTION TEST; HUMAN; MALE; OPHTHALMOSCOPY; OPTICAL COHERENCE TOMOGRAPHY; PERIMETRY; PROSPECTIVE STUDY; RETINA MACULA EDEMA; RETINAL SENSITIVITY; SENSITIVITY ANALYSIS; TREATMENT RESPONSE; VISUAL ACUITY; VISUAL FIELD DEFECT; VISUAL SYSTEM PARAMETERS;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; RETINA; RETINAL VEIN OCCLUSION; SENSORY THRESHOLDS; VISUAL ACUITY; VISUAL FIELD TESTS; VISUAL FIELDS;

EID: 84878904485     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3182794b06     Document Type: Article

References (24)

1. Weinberg D, Dodwell DG, Fern SA. Anatomy of arteriovenous crossings in branch retinal vein occlusion. Am J Ophthalmol 1990;109:298-302. (Pubitemid 20078949)
2. Wong TY, Mitchell P. The eye in hypertension [Review]. Lancet 2007;369:425-435.
3. Erratum in: Lancet 2007;369:2078. Wong, Tien [corrected to Wong, Tien Yin].
4. Wong TY, Larsen E, Klein R, et al. Cardiovascular risk factors for retinal vein occlusion and arteriolar emboli: the Atherosclerosis Risk in Communities & Cardiovascular Health studies. Ophthalmology 2005;112:540-547. (Pubitemid 41108850)
5. Klein R, Klein BE, Moss SE, Meuer SM. The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Trans Am Ophthalmol Soc 2000;98:133-141.
6. Branch Retinal Vein Occlusion Study Group. Argon laser photocoagulation for macular oedema in branch retinal vein occlusion. Am J Ophthalmol 1984;98:271-282.
7. Gewaily D, Greenberg PB. Intravitreal steroids versus observation for macular edema secondary to central retinal vein occlusion. Cochrane Database Syst Rev 2009;CD007324.
8. Campochiaro PA, Heier JS, Feiner L, et al; BRAVO Investigators. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010;117:1102-1112.
9. Rehak J, Rehak M. Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities. Curr Eye Res 2008;33:111-131. (Pubitemid 351302200)
10. Krepler K, Ergun E, Sacu S, et al. Intravitreal triamcinolone acetonide in patients with macular oedema due to branch retinal vein occlusion: a pilot study. Acta Ophthalmol Scand 2005;83:600-604. (Pubitemid 41488636)
11. Midena E, Radin PP, Convento E, Cavarzeran F. Macular automatic fundus perimetry threshold versus standard perimetry threshold. Eur J Ophthalmol 2007;17:63-68. (Pubitemid 46580600)
12. Kiss CG, Barisani-Asenbauer T, Simader C, Maca S, Schmidt-Erfurth U. Central visual field impairment during and following cystoid macular oedema. Br J Ophthalmol 2008;92:84-88.
13. Rohrschneider K, Springer C, Bultmann S, Volcker HE. Microperimetry- comparison between the Micro Perimeter 1 and scanning laser ophthalmoscope- fundus perimetry. Am J Ophthalmol 2005;139:125-134. (Pubitemid 40094849)
14. Springer C, Bultmann S, Volcker HE, Rohrschneider K. Fundus perimetrywith theMicro Perimeter 1 in normal individuals: comparison with conventional threshold perimetry. Ophthalmology 2005;112:848-854. (Pubitemid 40631504)
15. Heier JS, Campochiaro PA, Yau L, et al. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology 2012; 119:802-809.
16. Kim M, Yu SY, Kim ES, et al. Intravitreal ranibizumab for macular edema secondary to retinal vein occlusion. Ophthalmologica 2012;227:132-138.
17. Brown DM, Campochiaro PA, Bhisitkul RB, et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 2011;118:1594-1602.
18. Chang LK, Spaide RF, Klancnik JM, et al. Longer-term outcomes of a prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. Retina 2011;31:821-828.
19. Sacu S, Pemp B, Weigert G, et al. Response of retinal vessels and retrobulbar hemodynamics to intravitreal anti-VEGF treatment in eyes with branch retinal vein occlusion. Invest Ophthalmol Vis Sci 2011;52:3046-3050.
20. Kriechbaum K, Prager F, Geitzenauer W, et al. Association of retinal sensitivity and morphology during antiangiogenic treatment of retinal vein occlusion over one year. Ophthalmology 2009;116:2415-2421.
21. Goff MJ, Johnson RN, McDonald HR, et al. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration. Retina 2007;27:432-438. (Pubitemid 46624282)
22. Krebs I, Binder S, Stolba U, et al. Optical coherence tomography guided retreatment of photodynamic therapy. Br J Ophthalmol 2005;89:1184-1187. (Pubitemid 41224472)
23. Micelli Ferrari T, Sborgia L, Furino C, et al. Intravitreal triamcinolone acetonide: evaluation of retinal thickness changes measured by optical coherence tomography in diffuse diabetic macular edema. Eur J Ophthalmol 2004;14:321-324. (Pubitemid 39094811)
24. Kim JY, Park SP. Comparison between intravitreal bevacizumab and triamcinolone for macular edema secondary to branch retinal vein occlusion. Korean J Ophthalmol 2009; 23:259-265.